Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer.
Elevated serum levels of interleukin-37 correlate with poor prognosis in gastric cancer.
复制标题
血清白细胞介素 37 水平升高与胃癌预后不良相关。
DOI：
10.17235/reed.2019.6460/2019
复制
发表时间：
2019-11
影响因子：
2
通讯作者：
Chen Min-Bin
中科院分区：
文献类型：
--
作者：
Zhang Yan;Tang Min;Wang Xiao-Ge;Gu Jin-Hua;Zhou Li-Na;Jin Jun;Li Ping;Wang Li-Qiang;Chen Min-Bin
背景
白介素37(IL-37)是先天炎症和免疫反应的天然抑制因子。据报道，它还参与了癌症的发生和转移。本病例对照研究旨在探讨血清IL-37水平在胃癌中的作用。
方法
用双抗体夹心酶联免疫吸附试验测定了180例胃癌患者和100例健康人血清IL-37水平。评估IL-37水平与临床因素之间的关系。采用单因素和多因素分析探讨这些指标在胃癌预后中的意义。
结果
胃癌患者血清IL-37水平(5.606±0.837 pg/ml)显著高于健康对照组(2.364±0.210 pg/ml，P<0.001)。血清IL-37水平升高与低分化组织学类型(p=0.046)和晚期T分期(p=0.003)有关。Kaplan-Meier生存分析显示，高IL-37组的总生存期和无进展生存期较差(总生存期：39.0个月vs13.0个月，p<；0.001，无进展生存期：25.0月vs10.0个月，p<；0.001)。多因素分析显示血清IL-37是影响胃癌患者预后的独立因素(OS：危险比[HR]=1.842，95%CI：1.190~2.854，p=0.006；PFS：HR=1.547，95%CI：1.014~2.359，p=0.043)。
结论
综上所述，血清IL-37水平与胃癌患者总体生存率和无进展生存率差有关。IL-37可能是预测胃癌预后的一个潜在指标。
BACKGROUND
interleukin-37 (IL-37) is as a natural suppressor of the innate inflammatory and immune responses. It has also been reported to be involved in carcinogenesis and metastasis. The present case-control study was designed to investigate the role of serum levels of IL-37 in patients with gastric cancer.
METHODS
serum IL-37 levels were determined using the enzyme-linked immunosorbent assay in 180 patients diagnosed with gastric cancer and 100 healthy controls. The association between IL-37 levels and clinical factors was assessed. Univariate and multivariate analyses were performed to investigate the prognostic significance of these parameters in gastric cancer.
RESULTS
serum IL-37 levels in gastric cancer patients (5.606 ± 0.837 pg/ml) were significantly higher than those in healthy controls (2.364 ± 0.210 pg/ml, p < 0.001). High serum IL-37 levels were related to a poorly differentiated histologic type (p = 0.046) and advanced T stage (p = 0.003). The Kaplan-Meier survival analysis indicated that the high-IL-37 group had a poorer overall survival and progression-free survival (overall survival [OS]: 39.0 months vs 13.0 months, p < 0.001, progression-free survival [PFS]: 25.0 months vs 10.0 months, p < 0.001). Multivariate analyses showed serum IL-37 to be an independent prognostic factor for gastric cancer patients (OS: hazard ratios [HR] = 1.842, 95% CI: 1.190-2.854, p = 0.006; PFS: HR = 1.547, 95% CI: 1.014-2.359, p = 0.043).
CONCLUSIONS
in conclusion, serum IL-37 levels were associated with poor overall survival and progression-free survival in gastric cancer patients. IL-37 may be a potential predictor of prognosis in gastric cancer.